Clinicopathological features associated with CD44 and CD63 expression in breast cancer

Descripción del Articulo

Background: CD44 is a cell-surface transmembrane glycoprotein that participates in the regulation of many cellular processes, including cell division, adhesion, migration and stem-like characteristics. CD63 is involved in the exocytosis process. Objective: To evaluate the relationship between CD44 a...

Descripción completa

Detalles Bibliográficos
Autores: Castaneda, CA, Castillo, M, Sanchez, J, Bernabe, L, Tello, K, Suarez, N, Alatrista, R, Quiroz-Gil, X, Granda-Oblitas, A, Enciso, J, Enciso, N, Gomez, HL
Formato: artículo
Fecha de Publicación:2024
Institución:Instituto Nacional de Enfermedades Neoplásicas
Repositorio:INEN-Institucional
Lenguaje:inglés
OAI Identifier:oai:repositorio.inen.sld.pe:20.500.14703/377
Enlace del recurso:https: //doi.org/10.3332/ecancer.2024.1779
https://hdl.handle.net/20.500.14703/377
Nivel de acceso:acceso abierto
Materia:breast cancer
CD44
CD63
tumor-infiltrating lymphocytes
https://purl.org/pe-repo/ocde/ford#3.02.21
id INEN_e753b85421a9f22aa813dad4c5e2fce5
oai_identifier_str oai:repositorio.inen.sld.pe:20.500.14703/377
network_acronym_str INEN
network_name_str INEN-Institucional
repository_id_str .
spelling PublicationCastaneda, CACastillo, MSanchez, JBernabe, LTello, KSuarez, NAlatrista, RQuiroz-Gil, XGranda-Oblitas, AEnciso, JEnciso, NGomez, HL2025-05-05T17:29:35Z2025-05-05T17:29:35Z2024https: //doi.org/10.3332/ecancer.2024.1779https://hdl.handle.net/20.500.14703/377ecancermedicalscienceBackground: CD44 is a cell-surface transmembrane glycoprotein that participates in the regulation of many cellular processes, including cell division, adhesion, migration and stem-like characteristics. CD63 is involved in the exocytosis process. Objective: To evaluate the relationship between CD44 and CD63 expression and clinicopathological features, including tumor-infiltrating lymphocytes (TILs), phosphoinositide 3-kinase (PIK3CA) mutation and survival. Methodology: CD44 and CD63 were stained in samples from 101 breast cancer cases from Peruvian women. Results: Median age was 52 years, most were most were grade-3 (68%), estrogen receptor (ER)+ (64%) and stage II-III (92%). Median ki67 was 30%, median stromal TIL was 30% and PIK3CA mutation was found in 49%. Longer survival was associated with earlier stages (p = 0.016), lower ki67 (p = 0.023), ER+ (p = 0.034), luminal phenotype (p = 0.029) and recurrence (p < 0.001). CD44 was classified as high cell density staining in 57% and high intensity in 55%. High CD44 density was associated with younger age (p = 0.043), triple-negative phenotype (p = 0.035) and shorter survival (p = 0.005). High CD44 expression was associated with short survival (p = 0.005). High CD63 cell density was found in 56% of cases and was associated with ER-positive (p = 0.045), low TIL levels (p = 0.007), Luminal-A (p = 0.015) and low CD44 intensity (p = 0.032). Conclusion: CD44 expression was associated with aggressive features and low CD63 density staining.his work was supported by CONCYTEC (contract 007-2016-FONDECYT) and Universidad Cientifica del Sur.application/pdfengecancer Global FoundationUKinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/4.0/breast cancerCD44CD63tumor-infiltrating lymphocyteshttps://purl.org/pe-repo/ocde/ford#3.02.21Clinicopathological features associated with CD44 and CD63 expression in breast cancerinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionreponame:INEN-Institucionalinstname:Instituto Nacional de Enfermedades Neoplásicasinstacron:INENORIGINALcan-18-1779.pdfapplication/pdf481692https://repositorio.inen.sld.pe/backend/api/core/bitstreams/fa736027-d8e5-43d2-bfcb-0b5763f29945/downloada831fd7286b6614df5e31f37f8c94e61MD51trueAnonymousREADTEXTcan-18-1779.pdf.txtWritten by FormatFilter org.dspace.app.mediafilter.TikaTextExtractionFilter on 2025-08-22T08:02:33Z (GMT).Extracted texttext/plain42345https://repositorio.inen.sld.pe/backend/api/core/bitstreams/b264d97a-86d3-470c-85a5-a65d477a7a0b/downloada155244cd2ae7c59a183c7dd865df9a3MD52falseAnonymousREADTHUMBNAILcan-18-1779.pdf.jpgWritten by FormatFilter org.dspace.app.mediafilter.PDFBoxThumbnail on 2025-08-22T08:02:34Z (GMT).Generated Thumbnailimage/jpeg38072https://repositorio.inen.sld.pe/backend/api/core/bitstreams/5cd5e129-9fbf-49d2-8a12-f72c02a8955e/download2bf65bc094dc120333ade4ab4040c2ccMD53falseAnonymousREAD20.500.14703/377oai:repositorio.inen.sld.pe:20.500.14703/3772026-02-16T20:31:05.100Zhttps://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessopen.accesshttps://repositorio.inen.sld.peRepositorio del Instituto Nacional de Enfermedades Neoplásicasrepositorio@inen.sld.pe
dc.title.none.fl_str_mv Clinicopathological features associated with CD44 and CD63 expression in breast cancer
title Clinicopathological features associated with CD44 and CD63 expression in breast cancer
spellingShingle Clinicopathological features associated with CD44 and CD63 expression in breast cancer
Castaneda, CA
breast cancer
CD44
CD63
tumor-infiltrating lymphocytes
https://purl.org/pe-repo/ocde/ford#3.02.21
title_short Clinicopathological features associated with CD44 and CD63 expression in breast cancer
title_full Clinicopathological features associated with CD44 and CD63 expression in breast cancer
title_fullStr Clinicopathological features associated with CD44 and CD63 expression in breast cancer
title_full_unstemmed Clinicopathological features associated with CD44 and CD63 expression in breast cancer
title_sort Clinicopathological features associated with CD44 and CD63 expression in breast cancer
author Castaneda, CA
author_facet Castaneda, CA
Castillo, M
Sanchez, J
Bernabe, L
Tello, K
Suarez, N
Alatrista, R
Quiroz-Gil, X
Granda-Oblitas, A
Enciso, J
Enciso, N
Gomez, HL
author_role author
author2 Castillo, M
Sanchez, J
Bernabe, L
Tello, K
Suarez, N
Alatrista, R
Quiroz-Gil, X
Granda-Oblitas, A
Enciso, J
Enciso, N
Gomez, HL
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Castaneda, CA
Castillo, M
Sanchez, J
Bernabe, L
Tello, K
Suarez, N
Alatrista, R
Quiroz-Gil, X
Granda-Oblitas, A
Enciso, J
Enciso, N
Gomez, HL
dc.subject.none.fl_str_mv breast cancer
CD44
CD63
tumor-infiltrating lymphocytes
topic breast cancer
CD44
CD63
tumor-infiltrating lymphocytes
https://purl.org/pe-repo/ocde/ford#3.02.21
dc.subject.ocde.none.fl_str_mv https://purl.org/pe-repo/ocde/ford#3.02.21
description Background: CD44 is a cell-surface transmembrane glycoprotein that participates in the regulation of many cellular processes, including cell division, adhesion, migration and stem-like characteristics. CD63 is involved in the exocytosis process. Objective: To evaluate the relationship between CD44 and CD63 expression and clinicopathological features, including tumor-infiltrating lymphocytes (TILs), phosphoinositide 3-kinase (PIK3CA) mutation and survival. Methodology: CD44 and CD63 were stained in samples from 101 breast cancer cases from Peruvian women. Results: Median age was 52 years, most were most were grade-3 (68%), estrogen receptor (ER)+ (64%) and stage II-III (92%). Median ki67 was 30%, median stromal TIL was 30% and PIK3CA mutation was found in 49%. Longer survival was associated with earlier stages (p = 0.016), lower ki67 (p = 0.023), ER+ (p = 0.034), luminal phenotype (p = 0.029) and recurrence (p < 0.001). CD44 was classified as high cell density staining in 57% and high intensity in 55%. High CD44 density was associated with younger age (p = 0.043), triple-negative phenotype (p = 0.035) and shorter survival (p = 0.005). High CD44 expression was associated with short survival (p = 0.005). High CD63 cell density was found in 56% of cases and was associated with ER-positive (p = 0.045), low TIL levels (p = 0.007), Luminal-A (p = 0.015) and low CD44 intensity (p = 0.032). Conclusion: CD44 expression was associated with aggressive features and low CD63 density staining.
publishDate 2024
dc.date.accessioned.none.fl_str_mv 2025-05-05T17:29:35Z
dc.date.available.none.fl_str_mv 2025-05-05T17:29:35Z
dc.date.issued.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
dc.type.version.none.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.doi.none.fl_str_mv https: //doi.org/10.3332/ecancer.2024.1779
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.14703/377
dc.identifier.journal.none.fl_str_mv ecancermedicalscience
url https: //doi.org/10.3332/ecancer.2024.1779
https://hdl.handle.net/20.500.14703/377
identifier_str_mv ecancermedicalscience
dc.language.iso.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.none.fl_str_mv https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv ecancer Global Foundation
dc.publisher.country.none.fl_str_mv UK
publisher.none.fl_str_mv ecancer Global Foundation
dc.source.none.fl_str_mv reponame:INEN-Institucional
instname:Instituto Nacional de Enfermedades Neoplásicas
instacron:INEN
instname_str Instituto Nacional de Enfermedades Neoplásicas
instacron_str INEN
institution INEN
reponame_str INEN-Institucional
collection INEN-Institucional
bitstream.url.fl_str_mv https://repositorio.inen.sld.pe/backend/api/core/bitstreams/fa736027-d8e5-43d2-bfcb-0b5763f29945/download
https://repositorio.inen.sld.pe/backend/api/core/bitstreams/b264d97a-86d3-470c-85a5-a65d477a7a0b/download
https://repositorio.inen.sld.pe/backend/api/core/bitstreams/5cd5e129-9fbf-49d2-8a12-f72c02a8955e/download
bitstream.checksum.fl_str_mv a831fd7286b6614df5e31f37f8c94e61
a155244cd2ae7c59a183c7dd865df9a3
2bf65bc094dc120333ade4ab4040c2cc
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio del Instituto Nacional de Enfermedades Neoplásicas
repository.mail.fl_str_mv repositorio@inen.sld.pe
_version_ 1868438553726287872
score 12.821158
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).